ProPhase Labs (NASDAQ:PRPH) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a research report report published on Thursday morning. The firm issued a sell rating on the stock.

ProPhase Labs Stock Performance

NASDAQ PRPH opened at $0.49 on Thursday. The stock has a market capitalization of $11.70 million, a price-to-earnings ratio of -0.39 and a beta of -0.30. The stock has a 50-day moving average of $0.69 and a 200 day moving average of $1.89. The company has a current ratio of 1.47, a quick ratio of 1.33 and a debt-to-equity ratio of 0.48. ProPhase Labs has a twelve month low of $0.46 and a twelve month high of $7.48.

Institutional Investors Weigh In On ProPhase Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its holdings in ProPhase Labs by 9.2% during the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after purchasing an additional 13,590 shares in the last quarter. HighTower Advisors LLC raised its position in shares of ProPhase Labs by 18.3% during the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after purchasing an additional 27,673 shares during the last quarter. Finally, Sheets Smith Wealth Management purchased a new position in ProPhase Labs in the 4th quarter valued at about $158,000. Hedge funds and other institutional investors own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.